title: Effects of Yangxue Qingnao Granules on chronic cerebral circulation insufficiency: a randomized, double-blind, double-dummy, controlled multicentre trial.
abstract: BACKGROUND
  There is a great deal of interest in traditional Chinese medicine as a treatment for chronic cerebral circulation insufficiency (CCCI). In the present study, we evaluated the efficacy and safety of Yangxue Qingnao Granules (YXQNG) as a monotherapy in patients with CCCI.
  
  
  METHODS
  From July 2007 to May 2010, 273 patients with CCCI at nine centres in China were randomly assigned to receive either YXQNG with nimodipine placebo (n= 140, 12 g/day) or nimodipine with YXQNG placebo (n= 133, 30 mg/day) for 8 weeks. The primary end points after 8 weeks of treatment were changes from baseline in severity of headache, heavy-headed feeling, dizziness and sleep disorder.
  
  
  RESULTS
  The mean baseline levels of headache, heavy-headed feeling, dizziness and sleep disorder were comparable between the two groups. Both therapies significantly improved these symptoms after 8 weeks of treatment (P < 0.001). Compared with nimodipine therapy, YXQNG resulted in similar reductions in these symptoms. No adverse effects were observed in the YXQNG group.
  
  
  CONCLUSIONS
  These data demonstrate that YXQNG as a monotherapy were as effective as nimodipine monotherapy in improving the symptoms of CCCI. It is well-tolerated and may have an important place in the management of this condition. Whether a combination of these two medicines will increase therapeutic efficacy deserves further clinical investigation.
authors.affiliation: Department of Neurology, Second Affiliated Clinical College of Fujian University of Traditional Chinese Medicine, China.
authors.forename: Chenghan
authors.initials: C
authors.lastname: Wu
authors.forename: Lianming
authors.initials: L
authors.lastname: Liao
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Yan
authors.forename: Meide
authors.initials: M
authors.lastname: Li
authors.forename: Songying
authors.initials: S
authors.lastname: Wu
authors.forename: Jinmin
authors.initials: J
authors.lastname: Wang
authors.forename: Jushan
authors.initials: J
authors.lastname: Lin
authors.forename: Shiju
authors.initials: S
authors.lastname: Li
authors.forename: Lili
authors.initials: L
authors.lastname: Gao
authors.forename: Jian
authors.initials: J
authors.lastname: DU
authors.forename: Renmin
authors.initials: R
authors.lastname: Yang
mesh_terms: D000328:Adult; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D002681:China; D004244:Dizziness / Q000188:drug therapy* / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004365:Drugs, Chinese Herbal / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009553:Nimodipine / Q000627:therapeutic use; D008517:Phytotherapy; D012720:Severity of Illness Index; D012893:Sleep Wake Disorders / Q000188:drug therapy* / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use; D014717:Vertigo / Q000188:drug therapy* / Q000209:etiology
chemical_list: D004365:Drugs, Chinese Herbal; D014665:Vasodilator Agents; D009553:Nimodipine